Plasmodium vivax is an important cause of malaria, associated with a significant public
health burden. Whilst enhanced malaria-control activities have successfully reduced the …

Plasmodium vivax and Plasmodium ovale form dormant liver hypnozoites that can reactivate
weeks to months following initial infection. Malaria recurrences caused by relapses are an …

Like all fields of medicine, Infectious Diseases is rife with dogma that underpins much
clinical practice. In this study, we discuss 2 specific examples of historical practice that have …

Tafenoquine is a newly licensed antimalarial drug for the radical cure of Plasmodium vivax
malaria. The mechanism of action and optimal dosing are uncertain. We pooled individual …

Background Primaquine radical cure is used to treat dormant liver-stage parasites and
prevent relapsing Plasmodium vivax malaria but is limited by concerns of haemolysis. We …

Plasmodium vivax is the most geographically widespread human malaria parasite. Global
malaria efforts have been less successful at reducing the burden of P. vivax compared to P …

The technical genesis and practice of 8-aminoquinoline therapy of latent malaria offer
singular scientific, clinical, and public health insights. The 8-aminoquinolines brought …

The deployment of artesunate for severe malaria and the artemisinin combination therapies
(ACTs) for uncomplicated malaria has been a major advance in antimalarial therapeutics …

Plasmodium vivax is the most geographically widespread cause of human malaria and is
responsible for the majority of cases outside of the African continent. While great progress …

Background In most of the Americas, the recommended treatment to prevent relapse of
Plasmodium vivax malaria is primaquine at a total dose of 3.5 mg per kilogram of body …